RxDoctor Payments Data

Jessica Tucker, DO

Family Medicine · Brea, CANPI 1790940203

Payments from drug & device makers

$2,128in general payments, 2019–2025

Across 99 payments — averaging $21.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$415
  • Pfizer$243
  • Lilly USA, LLC$212
  • Amgen$201
  • Novo Nordisk$189
  • GSK$158
  • plus $710 from 14 others

What the payments were for

  • Consulting fees$201%
  • Food & beverage$2,10399%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,128 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$45,453
Medicare patients
115
Services billed
471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin33$44,531
EliquisApixaban45$40,346
MyrbetriqMirabegron36$36,001
Synjardy XrEmpagliflozin/Metformin Hcl27$34,982
JanuviaSitagliptin Phosphate41$34,543
OzempicSemaglutide28$31,739
FarxigaDapagliflozin Propanediol28$20,288
MounjaroTirzepatide13$18,893
TrulicityDulaglutide13$15,651
TradjentaLinagliptin12$6,447
SynthroidLevothyroxine Sodium44$3,699
Atorvastatin Calcium286$2,797
Levothyroxine Sodium130$1,869
Rosuvastatin Calcium77$1,573
Bupropion XlBupropion Hcl61$1,534

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$92$85,96072 claims
PfizerEliquis$243$40,34645 claims
Lilly USA, LLCMounjaro, Trulicity$212$34,54426 claims
MerckJanuvia$122$34,54341 claims
Novo NordiskOzempic$189$31,73928 claims
AstraZenecaFarxiga$415$20,28828 claims
AbbVieSynthroid$17$3,69944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Brea

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →